Scottish biotech firm’s shares jump 20% as China food allergy test approved

0
39
Shared Hosting - from $2.88/mo

SHARES in Omega Diagnostics rose almost 20 per cent after it posted news of approval for a food intolerance and allergy test 
in China.

The Alva-based biotech company’s shares reached 9.1p, up 19.7% on the report to the London Stock Exchange despite a delay in the deployment of its HIV testing kit in Nigeria.

The trading update in advance of its final results for the year ended March 31, 2020 included an impact assessment of the coronavirus pandemic, saying at this stage it has seen “minimal impact” from the outbreak on its food intolerance technology business and it expects revenues to be in-line with market expectation.

READ MORE: Ian McConnell: This is why employers must do right thing at height of coronavirus crisis – and later

The company announced that the National Medical Products Administration, formerly the China Food and Drug Administration, has approved its Food Detective test for laboratory use in China.

Omega, which specialises in tests for allergies, food intolerances and infectious diseases, said: “Our development team, working in conjunction with our distribution partner, has performed exceptionally well in developing a Chinese version of the Food Detective test and obtaining regulatory approval with the NMPA during what has been a difficult few months for everyone concerned throughout the world.”

Colin King, Omega chief executive, said: “I am delighted to receive the approval for one of our key strategic goals at this point in time. This is an excellent reward for all the hard work put in by both our and our partner’s teams, especially in these challenging times.”

READ MORE: Accountants warned on virus fall-out response by recruiters

He said: “We will now focus our efforts to achieving the self-test approval in China in conjunction with 
our partner.”

The firm said that after the January announcement that it had received approval from the Nigerian Federal Ministry of Health for its Visitect CD4 350 test to be deployed throughout the country, it has been told that ongoing work by purchasing agencies to analyse and set demand has taken longer than expected.

Omega said it is “in the process of stress-testing our business forecasts to include mitigation measures available to us”.

It has used £611,000 of a £2 million overdraft and 
expects EBITDA for the year ended March 31, 2020 
to be between £700,000 to £750,000.


Shops across Scotland are closing. Newspaper sales are falling. But we’ve chosen to keep our coverage of the coronavirus crisis free because it’s so important for the people of Scotland to stay informed during this difficult time.

However, producing The Herald’s unrivalled analysis, insight and opinion on a daily basis still costs money, and we need your support to sustain our trusted, quality journalism.

To help us get through this, we’re asking readers to take a digital subscription to The Herald. You can sign up now for just £2 for two months.

If you choose to sign up, we’ll offer a faster loading, advert-light experience – and deliver a digital version of the print product to your device every day. Click here to help The Herald: https://www.heraldscotland.com/subscribe/ Thank you, and stay safe.  



Source link

Shared Hosting - from $2.88/mo

LEAVE A REPLY

Please enter your comment!
Please enter your name here